Last reviewed · How we verify

Opioid Anesthetics

Kasr El Aini Hospital · Phase 3 active Small molecule

Opioid anesthetics bind to opioid receptors in the central nervous system to produce analgesia, sedation, and unconsciousness for surgical procedures.

Opioid anesthetics bind to opioid receptors in the central nervous system to produce analgesia, sedation, and unconsciousness for surgical procedures. Used for Induction and maintenance of general anesthesia, Analgesia during surgical procedures.

At a glance

Generic nameOpioid Anesthetics
Also known asOA, IV fentanyl, Opioid-based regimen, Opioid-based anesthetic, Opioid consumption during general anesthesia
SponsorKasr El Aini Hospital
Drug classOpioid agonist
TargetMu opioid receptor (primary); delta and kappa opioid receptors (secondary)
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhasePhase 3

Mechanism of action

Opioid anesthetics work by activating mu, delta, and kappa opioid receptors throughout the brain and spinal cord, suppressing pain signal transmission and producing profound analgesia combined with sedative and hypnotic effects. Common agents in this class (such as remifentanil, sufentanil, and fentanyl) are used as primary anesthetic agents or adjuncts during general anesthesia to provide rapid onset, titratable depth of anesthesia, and quick recovery.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: